811 related articles for article (PubMed ID: 31515704)
1. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
5. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Hayashi K; McDermott GC; Vanni KMM; Kowalski E; Qian G; Bade K; Saavedra A; Dieudé P; Dellaripa PF; Doyle TJ; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152312. PubMed ID: 38056314
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.
Kelly CA; Saravanan V; Nisar M; Arthanari S; Woodhead FA; Price-Forbes AN; Dawson J; Sathi N; Ahmad Y; Koduri G; Young A;
Rheumatology (Oxford); 2014 Sep; 53(9):1676-82. PubMed ID: 24758887
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
Yang M; Wu Y; Liu X; Zhao C; Li T; Li T; Zhang X; Jiang H; Mao B; Liu W
Respir Med; 2023 Sep; 216():107329. PubMed ID: 37315742
[TBL] [Abstract][Full Text] [Related]
9. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
Raimundo K; Solomon JJ; Olson AL; Kong AM; Cole AL; Fischer A; Swigris JJ
J Rheumatol; 2019 Apr; 46(4):360-369. PubMed ID: 30442831
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options.
Chen N; Diao CY; Gao J; Zhao DB
Semin Arthritis Rheum; 2022 Aug; 55():152004. PubMed ID: 35472663
[TBL] [Abstract][Full Text] [Related]
12. Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment.
Pugashetti JV; Lee JS
Semin Respir Crit Care Med; 2024 Jun; 45(3):329-341. PubMed ID: 38484788
[TBL] [Abstract][Full Text] [Related]
13. Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development.
Jeong E; Hong H; Lee YA; Kim KS
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473928
[TBL] [Abstract][Full Text] [Related]
14. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Xie M; Zhu C; Ye Y
BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
Wu C; Lin H; Zhang X
Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
[TBL] [Abstract][Full Text] [Related]
16. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
[TBL] [Abstract][Full Text] [Related]
17. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A
BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
[TBL] [Abstract][Full Text] [Related]
19. Assessment of interstitial lung disease among black rheumatoid arthritis patients.
McFarlane IM; Zhaz SY; Bhamra MS; Burza A; Kolla S; Alvarez MR; Koci K; Taklalsingh N; Pathiparampil J; Freeman L; Kaplan I; Kabani N; Ozeri DJ; Watler E; Frefer M; Vaitkus V; Matthew K; Arroyo-Mercado F; Lyo H; Zrodlowski T; Feoktistov A; Sanchez R; Sorrento C; Soliman F; Valdez FR; Dronamraju V; Trevisonno M; Grant C; Clerger G; Amin K; Dawkins M; Green J; Moon J; Fahmy S; Waite SA
Clin Rheumatol; 2019 Dec; 38(12):3413-3424. PubMed ID: 31471819
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.
Sparks JA; He X; Huang J; Fletcher EA; Zaccardelli A; Friedlander HM; Gill RR; Hatabu H; Nishino M; Murphy DJ; Iannaccone CK; Mahmoud TG; Frits ML; Lu B; Rosas IO; Dellaripa PF; Weinblatt ME; Karlson EW; Shadick NA; Doyle TJ
Arthritis Rheumatol; 2019 Sep; 71(9):1472-1482. PubMed ID: 30951251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
